MARKET

IMCR

IMCR

Immunocore Holdings Plc
NASDAQ
28.05
-0.71
-2.47%
After Hours: 28.05 0 0.00% 17:28 05/15 EDT
OPEN
28.73
PREV CLOSE
28.76
HIGH
28.75
LOW
27.83
VOLUME
194.93K
TURNOVER
--
52 WEEK HIGH
40.71
52 WEEK LOW
27.44
MARKET CAP
1.43B
P/E (TTM)
-50.3229
1D
5D
1M
3M
1Y
5Y
1D
A Look At Immunocore Holdings (IMCR) Valuation After Strong First Quarter 2026 Results
Simply Wall St · 1d ago
Immunocore publishes corporate presentation on bispecific soluble TCR immunomodulating medicines
PUBT · 3d ago
Weekly Report: what happened at IMCR last week (0504-0508)?
Weekly Report · 5d ago
Immunocore (IMCR) Is Up 9.7% After Strong Q1 Results And KIMMTRAK Survival Data Release
Simply Wall St · 5d ago
Immunocore (IMCR) Returns To Quarterly Profit And Tests Bearish Profitability Narratives
Simply Wall St · 05/08 14:44
Mizuho Securities Keeps Their Hold Rating on Immunocore Holdings (IMCR)
TipRanks · 05/08 13:22
Assessing Immunocore Holdings (IMCR) Valuation After Q1 2026 Results And New Phase 3 Survival Data
Simply Wall St · 05/07 13:46
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Immunocore Holdings (IMCR) and Eli Lilly & Co (LLY)
TipRanks · 05/07 12:50
More
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Webull offers Immunocore Holdings PLC - ADR stock information, including NASDAQ: IMCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMCR stock methods without spending real money on the virtual paper trading platform.